Hereditary Transthyretin Amyloidosis (hATTR)

Money on the Move: June 30 – July 6

Biology, Business, CAR-T Therapy, Clinical Trials, CRISPR, Financing, Financing, Hereditary Transthyretin Amyloidosis (hATTR), Initial Public Offering (IPO), Nasdaq, Neuromodulation, Pulmonary Arterial Hypertension, R&D, Series A, Series B, Series C Financing, Shares

The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.

FDA Approves Record-Breaking 59 Novel Drugs in 2018

Approvals, Calcitonin Gene-Related Peptide (CGRP), Cancer, Dravet syndrome, Epilepsy, Fabry Disease, FDA, FDA/Regulatory, First-In-Class, Hereditary Transthyretin Amyloidosis (hATTR), Migraine, New Molecular Entities, Polyneuropathy, RNA Interference (RNAi), Seizures

Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

Akcea and Ionis Announce EU Approval of Tegsedi

European Commission, FDA/Regulatory, Hereditary Transthyretin Amyloidosis (hATTR), Neuropathy, RNAi therapeutics

Akcea and Ionis’ Tegsedi (inotersen) received marketing authorization approval from the European Commission for treating stage 1 or stage 2 polyneuropathy in adults with hATTR.